Environmental, Social and Governance Report 2024/25 2024/25年度環境、社會及管治報告 CONTENT PAGE 目錄 | About the Group | 關於本集團 | 2 | | --- | --- | --- | | About the Report | 關於本報告 | 2 | | Scope and Reporting Period | 範圍及報告期間 | 3 | | Reporting Principles | 報告原則 | 3 | | Confirmation and Approval | 確認及批准 | 4 | | Sustainability Governance | 可持續發展管治 | 4 | | Stakeholders Engagement and Materiality | 持份者參與及重要性 | 4 | | Feedback | 反饋 | 7 | | Environmental Aspect | 環境層面 | 8 | | Emission | 排放 | 10 | | Use of Resources | 資源利用 | 15 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內 容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 股東週年大會通告 茲通告金威醫療集團有限公司（「本公司」）謹訂於二零二五年九月十九日（星期五）下午 十二時正假座香港上環文咸東街35-45B號2樓舉行股東週年大會（「股東週年大會」），以 考慮及酌情通過下列決議案為本公司決議案（無論有否修訂）： 普通決議案 1 1. 省覽、考慮及採納本公司截至二零二五年三月三十一日止年度之經審核綜合財務 報表及董事（「董事」）與核數師報告； 2. (a) 重選吳志龍先生為執行董事； (b) 重選黃嘉慧女士為獨立非執行董事；及 (c) 授權董事會（「董事會」）釐定董事酬金； 3. 續聘國衛會計師事務所有限公司為本公司核數師，並授權董事會釐定其酬金。 作為特別事項，考慮及酌情通過（不論有否修訂）下文提呈之第4至第6項決議案為普通 決議案： 4. 「動議： 2 (a) 在本決議案(c)段之規限下，根據香港聯合交易所有限公司（「聯交所」）GEM （「 GEM 」）證券上市規則，謹 ...

此乃要件 請即處理 （股份代號 ： 8143） （於開曼群島註冊成立之有限公司） (1)建議授出發行及購回股份之一般授權； (2)建議重選退任董事及繼續委任 任職超過九年之獨立非執行董事； 及 (3)股東週年大會通告 本公司謹訂於二零二五年九月十九日（星期五）下午十二時正假座香港上環文咸東街35-45B號2樓舉行 股東週年大會（「股東週年大會」），召開大會之通告載於本通函第18至23頁。本通函隨附股東週年大會 適用之代表委任表格。不論 閣下能否出席股東週年大會，務請 閣下按照代表委任表格印備指示填 妥表格，並盡快交回本公司香港股份過戶登記分處卓佳證券登記有限公司，地址為香港夏慤道16號遠 東金融中心17樓，惟無論如何必須於股東週年大會指定舉行時間四十八小時前（即不遲於二零二五年 九月十七日（星期三）下午十二時正（香港時間））或有關會議之任何續會舉行時間四十八小時前交回。填 妥及交回隨附之代表委任表格後， 閣下仍可依願親身出席有關大會或其任何續會並於會上投票，及 於該情況下，先前提交之代表委任表格將被視作撤回論。 本通函將自其刊發日期起最少一連七日載於香港聯合交易所有限公司網站(www.hkexnews.hk) ...

Should you have any queries relating to any of the above matters, please call the Branch Share Registrar's telephone hotline at (852) 2980 1333 during business hours from 9:00 a.m. to 6:00 p.m., Monday to Friday (excluding public holidays). (Stock Code 股份代號 ： 8143) (incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立之有限公司） NOTIFICATION LETTER 通知信函 Dear Non-registered Shareholder(s) (Note 1) , 31 July 2025 Good Fellow Healthcare Holdings Limited (the "Company") Notification of publication o ...

(Stock Code 股份代號 ： 8143) (incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立之有限公司） NOTIFICATION LETTER 通知信函 31 July 2025 Dear Registered Shareholder(s), Good Fellow Healthcare Holdings Limited (the "Company") 各位登記股東： 金威醫療集團有限公司（「本公司」） 日期為2025年7月31日載有股東週年大會通告及代表委任表格之通函之發佈通知（統稱「本次公司通訊」） 本公司的本次公司通訊之中、英文版本已分別上載於本公司網站www.gf-healthcare.com及香港聯合交易所有限公司（「聯交所」）之網站(www.hkexnews.hk)。 閣下可於公司網站 主頁「投資者關係」項下閱覽本次公司通訊及日後所有公司通訊 （附註1） 。如 閣下已選擇收取公司通訊的印刷本，隨函附上 閣下已選擇本次公司通訊之語言版本。 Notification of publication of ...

Incorporated in the Cayman Islands with limited liability 於開曼群島註冊成立之有限公司 (Stock Code 股份代號 ：8143) A N N U A L R E P O R T 年 報 2 0 2 4 / 2 5 CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE "STOCK EXCHANGE") GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies a ...

（股份代號 ： 8143） （於開曼群島註冊成立之有限公司） 截至二零二五年三月三十一日止年度之 全年業績公告 香港聯合交易所有限公司（「聯交所」）GEM（「GEM」）之特色 GEM之地位，乃為相比起其他在聯交所上市之公司帶有較高投資風險之中小型公司提供一個 上市之市場。有意投資之人士應了解投資於該等公司之潛在風險，並應經過審慎周詳之考慮 後方作出投資決定。 香港交易及結算所有限公司以及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致之任何損失承擔任何責任。 本公告乃根據GEM證券上市規則（「GEM上市規則」）提供有關金威醫療集團有限公司（「本公 司」）之資料，本公司之各董事（「董事」）願就本公告之內容共同及個別承擔全部責任。各董事在 作出一切合理查詢後確認，據彼等所深知及確信，本公告所載之資料於各重大方面均屬準確 完整，且無誤導或欺騙成分，而本公告亦無遺漏其他事實，以致本公告所載任何陳述或本公告 有所誤導。 1 財務概要 本集團截至二零二五年三月三十一日止財政年度之業績概要如下： 由於在GEM上市之公 ...

Summary of Key Points Core Viewpoint - As of May 28, a total of 65 stocks reached their 52-week highs, with notable performances from Kingway Medical Holdings (08559), China Silver Technology (00515), and Honghui Group (00183) leading the list with high rates of increase [1]. Group 1: Stocks Reaching 52-Week Highs - Kingway Medical Holdings (08559) achieved a closing price of 0.027 with a peak of 0.045, marking a high rate of 32.35% [1]. - China Silver Technology (00515) closed at 0.280, reaching a maximum of 0.305, resulting in a high rate of 28.15% [1]. - Honghui Group (00183) had a closing price of 0.255, with a peak price of 0.255, reflecting a high rate of 27.50% [1]. - Other notable stocks include Emperor Watch and Jewellery (00887) with a high rate of 27.14% and Sogo Department Store (00312) at 21.79% [1]. Group 2: Additional Stocks with Significant Increases - Lehua Entertainment (02306) reached a high rate of 13.73% with a closing price of 2.540 [1]. - Kingway Medical (08143) had a closing price of 0.124 and a peak of 0.230, resulting in a high rate of 10.05% [1]. - Other stocks with notable increases include Zhu Feng Gold (01815) at 6.98% and Yaoshi Bang (09885) at 6.68% [1]. Group 3: Stocks with Lower Performance - The report also includes stocks that did not perform as well, with some reaching their 52-week lows, such as China Parenting Network (01736) with a low rate of -14.40% [2]. - XI Nan Tes-U (09366) and XI Nan Tes (07366) also showed declines of -10.08% and -8.60% respectively [2]. - Other stocks like He Fu Hui Huang (00733) and Pai Ge Biomedical-B (02565) experienced decreases of -7.04% and -6.95% [2].

Financial Performance - For the six months ended September 30, 2024, the group recorded total revenue of approximately HKD 10,435,000, a decrease of about 60.05% compared to HKD 26,125,000 for the same period in 2023[4] - The profit attributable to owners of the company for the six months ended September 30, 2024, was approximately HKD 7,602,000, compared to a loss of HKD 7,160,000 in the same period of 2023[4] - The operating profit for the six months ended September 30, 2024, was HKD 7,749,000, compared to an operating loss of HKD 6,201,000 in the same period of 2023[5] - The company reported a total comprehensive income of HKD 7,265,000 for the period, compared to a total comprehensive loss of HKD 8,215,000 in the same period of 2023[8] - The group recorded a profit attributable to owners of approximately HKD 7,602,000, compared to a loss of HKD 7,161,000 in the previous year, mainly due to the recognition of a gain of approximately HKD 10,458,000 from the sale of a subsidiary[44] Earnings and Losses - The basic and diluted earnings per share for the period were HKD 1.349, compared to a loss per share of HKD 1.270 in the same period of 2023[8] - Basic loss per share for the six months ended September 30, 2024, was HKD 0.0135, compared to a loss of HKD 0.0127 in 2023, reflecting a slight increase in loss per share[29] - The company recorded a loss of HKD 7,161,000 for the period, with cumulative losses reaching HKD 713,666,000[12] Assets and Liabilities - The total assets as of September 30, 2024, amounted to HKD 24,668,000, a decrease from HKD 29,146,000 as of March 31, 2024[9] - The total liabilities as of September 30, 2024, were HKD 15,996,000, down from HKD 27,739,000 as of March 31, 2024[11] - The equity attributable to owners of the company increased to HKD 11,693,000 as of September 30, 2024, compared to HKD 4,357,000 as of March 31, 2024[9] - The total current assets as of September 30, 2024, were approximately HKD 6,560,000, compared to HKD 8,705,000 as of March 31, 2024[50] - The total current liabilities as of September 30, 2024, were approximately HKD 14,662,000, down from HKD 25,615,000 as of March 31, 2024[50] Cash Flow - The net cash generated from operating activities was HKD 476,000, down from HKD 909,000 in the previous year[15] - The company experienced a net cash decrease of HKD 2,652,000, compared to a decrease of HKD 13,038,000 in the same period last year[15] - The company's cash and cash equivalents at the end of the period were HKD 1,630,000, down from HKD 4,983,000 at the end of the previous year[15] - The total cash and cash equivalents as of September 30, 2024, were approximately HKD 1,630,000, down from HKD 3,644,000 as of March 31, 2024[50] Expenses - The total comprehensive expenses for the period amounted to HKD 8,215,000, compared to HKD 7,336,000 in the previous year[15] - Sales and distribution expenses for the review period were approximately HKD 1,549,000, down about 55.98% from HKD 3,519,000 in the previous year[44] - Administrative expenses were approximately HKD 9,459,000, representing a decrease of about 56.77% compared to HKD 21,881,000 last year, primarily due to reduced employee costs[44] Employee Information - The group employed 118 full-time employees as of September 30, 2024, down from 137 on March 31, 2024, with total employee costs amounting to approximately HKD 6,699,000 compared to HKD 11,214,000 in 2023[60] - Total employee benefits for key management personnel decreased to HKD 1,605,000 in 2024 from HKD 2,079,000 in 2023, reflecting a reduction in management compensation[40] Strategic Developments - The group is entering a transformation phase, shifting its strategic focus towards integrated digital healthcare and health management services[46] - The collaboration with Xiamen Yue'er Bay and Qingdao Yue'er Bay has been approved by relevant regulatory authorities, marking a significant step towards establishing a diversified and stable revenue base[47] Corporate Governance - The company has complied with the corporate governance code as per GEM listing rules during the review period[83] - The remuneration committee is responsible for determining the specific remuneration packages of all executive directors[84] - The nomination and corporate governance committee was established to review the board's structure and recommend suitable candidates for board membership[85] - The audit committee was established on November 2, 2001, consisting of three independent non-executive directors[87] - The audit committee's main responsibilities include ensuring adequate financial controls and monitoring risk management systems[87] Shareholder Information - As of September 30, 2024, Mr. Wu Zhi Long holds a beneficial interest in 11,800,000 shares, representing approximately 2.09% of the issued share capital[67] - The company has a total of 316,391,892 shares held by its beneficial owner, representing 56.13% of the issued shares[72] - Zheng Huixian holds 328,191,892 shares, accounting for 58.22% of the total issued shares[72] - New Hope International holds 68,643,507 shares, which is 12.18% of the total issued shares[72] Other Information - The company did not recommend the distribution of dividends for the six months ended September 30, 2024, consistent with the previous year[4] - The company has not applied any new accounting standards that have been issued but not yet effective, which would have a significant impact on its financial statements[20] - There were no significant events occurring after the reporting period[66] - The company has not purchased, sold, or redeemed any of its listed securities during the six months ending September 30, 2024[78] - There are no outstanding stock options under the stock option plan as of September 30, 2024[77]

Financial Performance - The Group's revenue for the year ended 31 March 2024 was approximately HK$38.962 million, a decrease of approximately 29.61% compared to HK$55.353 million in 2023[22]. - The operating loss for the year was approximately HK$16.036 million, compared to an operating loss of approximately HK$5.237 million in 2023[22]. - The net loss attributable to owners of the Company for the year was approximately HK$17.110 million, compared to a net loss of approximately HK$5.881 million in 2023[22]. - The segmental revenue from general hospital services was approximately HK$16.036 million, representing a decrease of approximately 29.61% compared to the previous year[23]. - Gross profit was approximately HK$18.674 million, a decrease of approximately 30.86% from HK$27.009 million in the previous year[32]. - Other revenue, primarily including government subsidy and bank interest income, amounted to approximately HK$0.149 million, a significant decrease from approximately HK$5.235 million in 2023[36]. - The Group recorded a net loss before taxation of approximately HK$16.344 million for the year ended 31 March 2024, an increase of approximately 189.22% compared to HK$5.651 million in 2023[52]. Operational Overview - The Group continues to operate one general hospital in Beijing and is allocating resources to explore business opportunities for expanding hospital services[23]. - The Group operated one general hospital in Beijing, continuing to focus on providing comprehensive hospital services[35]. - Management anticipates diversifying hospital services in the coming years to meet various patient needs[40]. - The Group is enhancing regulatory compliance and quality assurance measures to ensure uninterrupted operations and adherence to standards[65]. - The Group aims to improve patient experience through digital health solutions and exceptional customer service[64]. Financial Position - Total cash and bank balances decreased to approximately HK$3.644 million as at 31 March 2024, down from approximately HK$17.685 million in 2023[74]. - The current ratio of the Group was approximately 0.34 as at 31 March 2024, a decline from approximately 1.33 in 2023, indicating a decrease in liquidity[80]. - The Group's gearing ratio was maintained at 610.16% as at 31 March 2024, reflecting a high level of debt relative to equity[81]. - As of March 31, 2024, the total current assets of the Group were approximately HK$8,705,000, a decrease from approximately HK$27,062,000 as of March 31, 2023[84]. - The total current liabilities as of March 31, 2024, were approximately HK$25,615,000, compared to approximately HK$20,325,000 as of March 31, 2023[84]. Staffing and Expenses - The Group had 137 full-time employees as of March 31, 2024, a slight decrease from 139 in 2023[105]. - Staff costs for the year ended March 31, 2024, amounted to approximately HK$22.669 million, down from approximately HK$25.757 million in 2023, representing a decrease of about 12.1%[110]. - Selling and distribution expenses decreased by approximately 34.20% to approximately HK$8.918 million from HK$13.553 million in 2023[44]. - Administrative expenses decreased by approximately 14.66% to approximately HK$20.271 million from HK$23.754 million in 2023[45]. - Finance costs decreased by approximately 25.60% to approximately HK$0.308 million from HK$0.414 million in 2023[46]. Legal Matters - A civil complaint was filed against the group, seeking a refund of approximately RMB12.13 million (approximately HK$14.973 million) and liquidated damages of approximately RMB1.4 million (approximately HK$1.728 million)[120]. - Following a civil judgment, the group was ordered to return approximately RMB4.9 million (approximately HK$5.9 million) to China Merchants[124]. - A second civil complaint was received, seeking the refund of approximately RMB3.2 million (approximately HK$3.625 million) by Edinburgh International Diabetes[128]. - As of the date of the report, Edinburgh Hospital Management had yet to make payment of approximately RMB5.9 million to China Merchants pursuant to the civil judgment[127]. - China Merchants is seeking the return of an investment balance of approximately RMB 3,200,000 (equivalent to approximately HK$3,625,000) from Edinburgh International Diabetes as per Civil Complaint II[131]. Corporate Governance - The company has adopted the principles and code provisions of the Corporate Governance Code as its corporate governance practices[180]. - The company has complied with the applicable code provisions in the Corporate Governance Code throughout the year ended March 31, 2024[181]. - The Board currently comprises two executive Directors and three independent non-executive Directors[196]. - The company has established three committees: the Audit Committee, the Nomination and Corporate Governance Committee, and the Remuneration Committee[192]. - The company is committed to achieving a high standard of corporate governance to protect and promote the interests of all shareholders[180]. Strategic Focus and Risks - The company identified potential market risks due to recent restructuring of PRC government healthcare agencies, which may impact hospital operations and management[153]. - The financial condition and operational performance of the Group may be influenced by multiple risks and uncertainties, including recent restructuring of health-related central departments by the Chinese government[156]. - The Group's future outlook remains cautious due to the potential for evolving risks and uncertainties in the healthcare market[156]. - The Group's market promotion plans and collaborations may face risks due to potential impacts from local government policy changes[157]. - The management team includes experienced professionals with backgrounds in business management, strategic planning, and risk management, enhancing the Group's operational capabilities[160][161].